GLP-1 Agonists and Muscle Loss: What the Research Shows and How to Preserve Lean Mass

Semaglutide and tirzepatide have transformed obesity medicine. The average person on tirzepatide loses 20–22% of their body weight; on semaglutide, 15–17%. Those are numbers that previously required bariatric surgery.

But there's a complication the prescribing literature doesn't emphasize enough: a meaningful portion of that weight loss comes from lean mass — muscle, bone, and organ tissue — not just fat.

For most people, this is manageable with the right strategy. For older adults, it can tip into clinically significant sarcopenia. For anyone who cares about long-term metabolic health, body composition, or athletic performance, it's something you need to actively counter.

This guide covers what the clinical trials actually show about lean mass loss on GLP-1 agonists, who is most at risk, and the evidence-based strategies that preserve muscle while still allowing the drugs to do their job.

How Much Lean Mass Do GLP-1 Drugs Actually Cause You to Lose?

The most rigorous data comes from body composition substudies nested inside the major clinical trials, using dual-energy X-ray absorptiometry (DXA) to track changes in fat mass and lean mass separately.

STEP-1 (Semaglutide 2.4 mg)

The STEP-1 trial demonstrated that semaglutide 2.4 mg produced ~15% total weight loss over 68 weeks. In body composition analyses, approximately 38–40% of the total weight lost came from lean mass — a proportion consistent with what's typically seen in calorie-restricted weight loss without exercise.

It's worth noting that "lean mass" on DXA includes more than skeletal muscle — it also captures liver glycogen, visceral organ reductions, and body water. Some researchers estimate that true skeletal muscle loss may be 20–25% of total weight lost, with the remainder from non-muscle lean compartments. Still, that figure represents meaningful muscle tissue in absolute terms.

SURMOUNT-1 (Tirzepatide 5, 10, 15 mg)

SURMOUNT-1 included a 160-participant DXA substudy that followed participants for 72 weeks. The findings, published in 2025 in Diabetes, Obesity and Metabolism, showed:

• Total weight change: −21.3% with tirzepatide vs. −5.3% with placebo
• Fat mass change: −33.9% with tirzepatide vs. −8.2% with placebo
• Lean mass change: −10.9% with tirzepatide vs. −2.6% with placebo
• Lean mass as a proportion of weight lost: approximately 25% for both tirzepatide and placebo groups

The ratio of fat mass to lean mass improved substantially with tirzepatide (from 0.93 to 0.70), indicating that body composition quality improved even as absolute lean mass declined. Tirzepatide appears modestly better than semaglutide at sparing lean mass relative to total weight lost — likely due to its dual GIP/GLP-1 mechanism — but the difference is incremental, not transformative.

What the Numbers Mean in Practice

On a 20 kg weight loss with tirzepatide, expect to lose roughly 5 kg of lean mass and 15 kg of fat. On a 15 kg loss with semaglutide, expect 4–6 kg of lean mass loss. These are population averages — individual variation is significant, and the strategies below can shift the ratio substantially in your favor.

Why Do GLP-1 Agonists Cause Lean Mass Loss?

GLP-1 receptor agonists work primarily by suppressing appetite and slowing gastric emptying, creating a sustained calorie deficit. The lean mass loss that follows is largely a consequence of that deficit — not a direct drug effect on muscle tissue.

When calorie intake drops sharply, the body draws energy from both fat stores and lean tissue. Without a stimulus to maintain muscle (resistance training) and without adequate protein to support muscle protein synthesis, the body has little incentive to preserve lean mass it's not actively using.

Several secondary mechanisms may amplify this effect:

1. Reduced protein intake: GLP-1 agonists suppress appetite broadly. Patients often meet their calorie targets while significantly under-eating protein — the primary substrate for muscle maintenance.
2. Reduced physical activity: Nausea, fatigue, and general malaise common in the early weeks of treatment can reduce exercise tolerance and output.
3. Suppressed anabolic hormones: Significant caloric restriction reduces IGF-1, testosterone, and other anabolic hormones that drive muscle protein synthesis.
4. Direct GLP-1 receptor effects: Emerging preclinical evidence suggests GLP-1 receptors are expressed on skeletal muscle cells, raising the possibility of direct effects — though the clinical significance in humans remains unclear.

Who Is Most at Risk?

Not everyone faces equal risk of clinically meaningful muscle loss on GLP-1 therapy.

Older Adults (≥65 years)

This is the group where muscle loss on GLP-1 agonists becomes a genuine clinical concern. Sarcopenia — age-related muscle loss — already accelerates after age 60, and superimposing a large pharmacological calorie deficit on an already-compromised neuromuscular system can cause disproportionate lean mass loss.

A 2025 retrospective cohort study examining 24-month outcomes in adults over 65 with type 2 diabetes found accelerated sarcopenia in semaglutide users, including significant reductions in handgrip strength — a validated proxy for whole-body muscle function — that became apparent after month 12. A British Journal of Pharmacology analysis published the same year flagged that muscle strength losses may be even more clinically significant than mass losses in this demographic.

Women

Women have lower baseline muscle mass than men and may be more susceptible to relative lean mass losses during caloric restriction. Data presented at the Endocrine Society's ENDO 2025 meeting indicated that women taking semaglutide showed greater lean mass reductions than men at comparable total weight losses — and that higher protein intake was particularly protective in female patients.

Sedentary Individuals

Patients who are physically inactive going into GLP-1 therapy have no resistance training stimulus to preserve muscle. The "use it or lose it" principle applies directly: without mechanical loading, muscle tissue becomes a metabolic liability during a calorie deficit.

Those Starting at Low Lean Mass

Individuals already at the low end of lean mass for their body weight — common in sarcopenic obesity, where excess fat coexists with inadequate muscle — are at greatest risk of tipping into clinical sarcopenia with aggressive pharmacological weight loss.

Strategy 1: Prioritize Protein Intake

Protein is the single most evidence-supported nutritional intervention for preserving lean mass during weight loss — and this holds specifically during GLP-1 therapy.

What the Research Shows

Data presented at ENDO 2025 demonstrated that higher protein intake significantly reduced lean mass loss in women taking semaglutide. A 2025 case series by Tinsley and Nadolsky in SAGE Open Medical Case Reports showed that GLP-1 patients who maintained consistent protein intake — combined with resistance training — experienced minimal lean soft tissue loss and in some cases actually increased lean tissue despite significant overall weight reduction.

A 2025 review published in PMC concluded that protein targets of 1.2–1.6 g per kilogram of body weight per day are appropriate for GLP-1 users, with some researchers recommending up to 1.5–1.7 g/kg for older adults or those at high sarcopenia risk.

How to Hit Your Targets

• Track protein deliberately. GLP-1 agonists suppress appetite broadly. Patients commonly meet their calorie goals while significantly under-eating protein. Tracking protein specifically — not just total calories — is the fix.
• Spread intake across meals. Muscle protein synthesis is maximized with 25–40 g of high-quality protein per meal across 3–4 meals. A single large protein bolus is less effective than distributed intake.
• Prioritize leucine-rich sources. Leucine is the primary anabolic amino acid. Whey protein, eggs, chicken, beef, and fish are all leucine-dense. Plant-based sources can work but require higher total amounts to deliver equivalent leucine.
• Use protein shakes strategically. For patients with GLP-1-related nausea or suppressed appetite, a protein shake is often easier to tolerate than a full meal — and prevents protein shortfalls on low-appetite days.

Strategy 2: Resistance Training Is Non-Negotiable

Exercise is the most powerful lever for preserving lean mass during GLP-1 therapy. Specifically resistance training — not cardio alone.

The Clinical Evidence

A 2024 randomized trial found that GLP-1 users who performed structured resistance training preserved approximately 60% more lean mass than those who did not exercise during treatment. Meta-analyses of calorie-restricted diets consistently show that resistance training can reduce fat-free mass loss by 50–95% compared to diet alone, depending on program adherence.

A 2025 Frontiers in Clinical Diabetes and Healthcare paper concluded that lifestyle prioritization — particularly resistance training — should be considered clinical standard of care alongside GLP-1 prescriptions, not an optional add-on.

The Minimum Effective Dose

You don't need to become a competitive powerlifter. The minimum effective program for lean mass preservation during weight loss looks like this:

• Frequency: 2–3 sessions per week
• Volume: 2–4 sets per major muscle group per session
• Intensity: 60–80% of 1-rep max, producing near-failure at 8–15 reps
• Progressive overload: Gradually increase weight or volume over time

Compound movements — squats, deadlifts, rows, presses, lunges — provide the best return per time invested by recruiting multiple large muscle groups simultaneously. For older adults or those with mobility limitations, machines, resistance bands, and progressive bodyweight exercises all provide adequate stimulus. The key requirement: the muscle must be loaded to near-fatigue.

Strategy 3: Time Protein Around Training

Combining protein timing with resistance training is more effective than either intervention alone. Consuming 25–40 g of protein within 2 hours of a resistance session — before or after — maximizes the anabolic response to exercise.

On GLP-1 therapy, where appetite is suppressed and protein intake is already at risk of being inadequate, protecting this peri-workout protein window becomes especially important.

Some evidence also supports a pre-sleep protein dose of 20–40 g of casein (slow-digesting) protein to sustain overnight muscle protein synthesis — potentially beneficial during extended caloric restriction.

Strategy 4: Monitor Body Composition, Not Just Weight

Scale weight is an inadequate metric for GLP-1 patients. A patient who loses 20 kg of fat and maintains lean mass has achieved something medically excellent — but the scale doesn't distinguish. Without body composition data, you can't tell the difference between high-quality weight loss and lean mass loss.

DXA scans provide the gold standard. For patients with significant weight loss goals, a baseline DXA scan at treatment initiation followed by repeat scans every 6–12 months gives the data needed to adjust protein intake and training accordingly.

Grip strength testing via handheld dynamometer is a validated, inexpensive proxy for whole-body muscle function — particularly useful for older patients. Declining grip strength during GLP-1 therapy is a clinical signal to intensify lean mass preservation strategies.

Bioelectrical impedance analysis (BIA) scales are less precise than DXA but accessible for at-home tracking. Good-quality BIA devices can track directional trends in lean mass with reasonable reliability between formal DXA appointments.

Strategy 5: Emerging Pharmaceutical Approaches

For high-risk patients — particularly older adults with documented sarcopenia — researchers are investigating pharmaceutical adjuncts to GLP-1 therapy that specifically protect lean mass.

Bimagrumab

Bimagrumab is a monoclonal antibody that blocks activin type II receptors, inhibiting the myostatin pathway that normally suppresses muscle growth. In the Phase 2b BELIEVE trial, bimagrumab combined with semaglutide 2.4 mg produced 22.1% total weight loss while blunting lean soft tissue loss by approximately 67–69% compared to semaglutide alone — a dramatic improvement in weight loss quality.

Eli Lilly discontinued its Phase IIb trial combining bimagrumab with tirzepatide in 2025 for strategic business reasons, though other combination studies remain ongoing. Bimagrumab is not yet commercially available for obesity indications.

Creatine Monohydrate

Creatine monohydrate is well-established for supporting lean mass and strength preservation during caloric restriction. At standard doses (3–5 g/day), it is inexpensive, safe, and backed by a robust evidence base. Multiple researchers have explicitly recommended creatine as an adjunct for GLP-1 patients engaged in resistance training.

Strategy 6: Peptide Adjuncts for Recovery Support

Some patients and clinicians are exploring peptide therapies as adjuncts to GLP-1 treatment — not to directly prevent muscle loss, but to support connective tissue integrity, recovery from training, and musculoskeletal health during rapid weight loss.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from a protein in human gastric juice. Preclinical research documents promotion of tendon-to-bone healing, angiogenesis, and musculoskeletal tissue repair. It has also been studied for gastroprotective effects — potentially relevant for GLP-1 patients experiencing GI side effects.

Human clinical trials remain limited, and BPC-157 is currently used off-label by patients seeking to support connective tissue integrity and training recovery during periods of high-volume training combined with pharmacological weight loss.

TB-500 (Thymosin Beta-4)

TB-500 is a synthetic form of Thymosin Beta-4, a protein involved in actin regulation and tissue repair. Its preclinical evidence base covers wound healing, cardiac tissue repair, and musculoskeletal recovery. It is similarly used off-label by some patients as a recovery adjunct during aggressive weight loss protocols.

Neither BPC-157 nor TB-500 replaces adequate protein intake and resistance training. Their potential role is as adjuncts supporting training recovery — not as primary lean mass preservers.

A Practical Summary Protocol

For a patient starting semaglutide or tirzepatide who wants to minimize lean mass loss:

If you are ≥65 years old, have pre-existing sarcopenia, or have lost significant lean mass in previous weight loss attempts, discuss body composition monitoring proactively with your prescribing clinician before starting GLP-1 therapy.

Frequently Asked Questions

Does stopping GLP-1 therapy cause muscle loss?
Weight regain after stopping semaglutide or tirzepatide is well-documented — and it typically occurs predominantly as fat, not lean mass. This can worsen body composition compared to baseline. Maintaining protein and training habits after stopping treatment is important.

Is tirzepatide better than semaglutide for lean mass preservation?
SURMOUNT-1 data suggests tirzepatide may preserve a slightly higher proportion of lean mass relative to total weight lost compared to semaglutide — possibly due to GIP receptor activity. The difference is modest, and both drugs require active lean mass preservation strategies.

Can I build muscle while on a GLP-1 agonist?
Yes, particularly if you are new to resistance training. Beginners can gain lean mass even in a caloric deficit ("newbie gains"). Experienced trainees are unlikely to add significant muscle while in a sustained deficit but can realistically minimize losses with the strategies above.

How much muscle loss is too much?
There's no universal threshold, but losing more than 30% of total weight loss as lean mass should prompt a reassessment of protein intake, training habits, and — for older adults — possible referral to a sarcopenia or sports medicine specialist.

The Bottom Line

GLP-1 agonists deliver extraordinary weight loss results, but the quality of that weight loss depends significantly on what you do alongside the medication. Roughly 25–40% of total weight lost on semaglutide or tirzepatide comes from lean mass — a proportion that can be meaningfully reduced with evidence-based strategies.

Adequate protein intake (1.2–1.6 g/kg/day), consistent resistance training (2–3×/week), and regular body composition monitoring are the three non-negotiable pillars. Creatine supplementation, strategic protein timing, and — for high-risk patients — emerging pharmaceutical adjuncts can further improve outcomes.

The goal isn't just a lower number on the scale. It's a leaner, stronger, metabolically healthier body. That outcome requires active effort on your part — and with the right protocol, it is absolutely achievable.